11-3-1998

Cytochalasins Useful in Providing Protection Against Nerve Cell Injury Associated with Neurodegenerative Disorders

Mark P. Mattson
University of Kentucky

Click here to let us know how access to this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/sbcoa_patents

Part of the Geriatrics Commons

Recommended Citation
https://uknowledge.uky.edu/sbcoa_patents/1

This Patent is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for inclusion in Sanders-Brown Center on Aging Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
CYTOCHALASINS USEFUL IN PROVIDING PROTECTION AGAINST NERVE CELL INJURY ASSOCIATED WITH NEURODEGENERATIVE DISORDERS

Inventor: Mark P. Mattson, Lexington, Ky.

Assignee: University of Kentucky Research Foundation, Lexington, Ky.

Filed: Oct. 23, 1995

References Cited

PUBLICATIONS


(Continued on next page.)

Primary Examiner—William R. A. Jarvis
Attorney, Agent, or Firm—Low, Price, Leblanc & Becker

ABSTRACT

The present invention relates to novel therapeutic uses of certain compounds to protect nerve cells from injury and death. The compounds include cytochalasin D and related analogs, and cytochalasin E and related analogs.

6 Claims, 15 Drawing Sheets
OTHER PUBLICATIONS


Koh, J.Y. et al., β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:315—320; 1990.


Mattson, M.P. et al., Calcium–destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res. 621:35–49; 1993.


FIG. 1A

FIG. 1B
**FIG. 1C**

The graph shows the intraneuronal calcium concentration over time (in seconds). The x-axis represents time, ranging from 0 to 200 seconds, and the y-axis represents the intraneuronal calcium concentration in nM (nanomolars). The graph includes four lines:
- Control
- KCl
- Aβ
- CyD + Aβ

**FIG. 1D**

A bar graph depicting the intraneuronal calcium concentration at different glutamate concentrations. The x-axis indicates glutamate concentrations of 10 µM, 50 µM, and 100 µM, while the y-axis represents the intraneuronal calcium concentration in nM. The graph compares control and Cytochalasin D treatments.
FIG. 3
**FIG. 5A**

Neuronal Survival (% of initial number)

Cytochalasin D Concentration (nM)

**FIG. 5B**

Neuronal Survival (% of initial number)

Glutamate Concentration (μM)
**FIG. 7**

Neuronal Survival (% of initial number) vs. A23187 Concentration (μM)

- Control
- Cytochalasin D

**FIG. 8**

Neuronal Survival (% of initial number) vs. Treatment

- Control
- 10 μM FeSO₄
- VitE
- NDGA
- 100 μM FeSO₄
FIG. 11A

Cytochalasin D

FIG. 11B

Control
Neuronal Survival (% of initial number)

**FIG. 13**

Control  | $\alpha$B  | Glut  | $\alpha$B + Glut  | CyD + $\alpha$B + Glut

**FIG. 14**

Control  | Colch  | $\alpha$B  | Colch + $\alpha$B  | CyE + $\alpha$B
Neuronal Survival (% of initial number)

Hydrogen Peroxide Concentration (μM)

FIG. 15
FIG. 16A

FIG. 16B
CYTOCHALASINS USEFUL IN PROVIDING PROTECTION AGAINST NERVE CELL INJURY ASSOCIATED WITH NEURODEGENERATIVE DISORDERS

FIELD OF THE INVENTION

The present invention relates to a novel therapeutic use of certain compounds to protect nerve cells from injury and death. The compounds include cytochalasin D and related analogs, and cytochalasin E and related analogs.

BACKGROUND OF THE INVENTION

Nerve cell injury and death leads to a number of neurodegenerative disorders such as Alzheimer’s disease and stroke.

The leading cause of dementia and the fourth leading cause of death in the developed world is Alzheimer’s disease which affects an estimated 10% of the population over 65 years of age in the United States. Alzheimer’s disease imposes a tremendous financial burden on afflicted individuals because they require prolonged care.

Affected individuals are at first forgetful. As this progressive disorder gradually worsens, these affected individuals, although able to recall occurrences in the distant past, are unable to remember recent events. Subsequently, speech, the ability to calculate, visuospatial orientation, judgment, and social behavior become progressively abnormal. Eventually, profound dementia sets in and frequently the individual dies of superimposed infections. The duration of diseases ranges from 3 to 10 years.

The diagnosis of Alzheimer’s disease is usually made on the basis of clinical history, neurological examination and laboratory tests that help to exclude other disorders, some of which are potentially treatable. Unfortunately, other than direct examination of brain tissue obtained by cerebral biopsy or at autopsy, no tests to establish a diagnosis of Alzheimer’s disease presently exist.

At autopsy, the brains of individuals with Alzheimer’s disease are usually smaller than normal for their age. Microscopic examination discloses four characteristic pathological features that are essential for the diagnosis of Alzheimer’s disease: neurofibrillary tangles, loss of specific population of nerve cells, senile plaques and deposits of amyloid.

Neurofibrillary tangles, that is, fibrillar inclusions within cell bodies of affected neurons, consist of abnormal filaments thought to be derived in part from cytoskeletal elements normally present in nerve cells. Neurofibrillary tangles consist of abnormal accumulations of cytoskeletal and other proteins whereas senile plaques consist of aggregates of amyloid β-peptide (Aβ). Major components of neurofibrillary tangles are the microtubule-associated protein tau, and ubiquitin, a “heat-shock” protein involved in targetting proteins for proteolytic degradation. Posttranslational alterations in tau such as phosphorylation, and disassociation of tau from microtubules may promote the assembly of tau into the abnormal straight and paired helical filaments that characterize neurofibrillary tangles. Although the mechanism leading to neurofibrillary degeneration is not clear, several observations suggest a role for dysregulation of neuronal calcium homeostasis with resultant elevations of intracellular free calcium concentration, [Ca\(^{2+}\)]. Among the evidence supporting this hypothesis is: experimentally induced elevations of [Ca\(^{2+}\)], in hippocampal neurons (in vitro and in vivo) can elicit antigenic, biochemical and ultrastructural changes in cytoskeletal proteins (tau and spectrin) similar to those seen in neurofibrillary tangles; neurons vulnerable to neurofibrillary degeneration bear high levels of glutamate receptors; aggregated Aβ can be neurotoxic and can render neurons vulnerable to excitotoxicity by a mechanism that involves destabilization of [Ca\(^{2+}\)] homeostasis. In addition, studies indicate that mitogen-activated protein (MAP) kinases can phosphorylate tau in a manner very similar to that observed in the paired helical filaments of Alzheimer’s disease, and MAP kinases are known to be activated glutamate and elevation of [Ca\(^{2+}\)].

Degeneration and death of certain populations of nerve cells occur in certain brainstem nuclei, the basal forebrain, the amygdala, the hippocampus and neocortex. In the brain, specific populations of nerve cells use specific neurotransmitters. Also, neurochemical studies have shown that the brains of individuals with Alzheimer’s disease exhibit a selective reduction in markers for certain neurotransmitter systems.

The third characteristic brain abnormality associated with Alzheimer’s disease is the presence of abundant senile plaques, composed of several elements: abnormal neurites (enlarged filament-containing axons and terminals), extracellular amyloid fibrils and non-neuronal reactive cells. The presence of plaques correlates with the presence of dementia and with the severity of loss of certain neurotransmitter markers, particularly cholinergic enzymes.

Localized in plaques and around cerebral blood vessels, amyloid is composed of a 4-kilodalton protein designated amyloid β-peptide. The amyloid β-peptide is a 40–42 amino acid peptide arising from a much larger membrane-spanning β-amylloid precursor protein (695–770 amino acids) which is a transmembrane glycoprotein that accumulates as diffuse (unaggregated) and compact (aggregated) plaques in the brain of victims of Alzheimer’s disease. The diffuse plaques are not associated with neuronal pathology, whereas compact Aβ is surrounded by degenerative neurites with characteristic cytoskeletal pathology. Cell culture studies have shown that Aβ can be directly neurotoxic, and can render neurons vulnerable to excitotoxicity and oxidative injury. The mechanism of Aβ toxicity is related to its secondary structure and appears to involve free radical-mediated damage to the plasma membrane and disruption of cellular calcium homeostasis resulting in elevated rest [Ca\(^{2+}\)], and increased [Ca\(^{2+}\)] responses to depolarization and excitatory amino acids.

The major pathway for β-amylloid precursor protein (βAPP) metabolism involves an enzymatic cleavage within the Aβ sequence and obviates deposition of amyloidogenic Aβ. On the other hand, Aβ is released from brain cells at low levels and is present in the cerebrospinal fluid at nanomolar concentrations indicating an alternative processing pathway of βAPP. A cleavage of βAPP at the N-terminus of Aβ leaves behind a C-terminal fragment of βAPP which contains potentially amyloidogenic Aβ. Some cases of inherited Alzheimer’s disease have been linked to mutations in βAPP which may alter processing of βAPP in a way that leads to increased production of Aβ. The link between altered metabolism of βAPP and neuronal injury in Alzheimer’s disease is supported by studies showing that synthetic Aβ peptides can be directly neurotoxic to primary cultures of hippocampal and cortical neurons, and can render neurons vulnerable to glutamate excitotoxicity, glucose deprivation, and oxidative injury. The neurotoxicity of Aβ is dependent upon its ability to form aggregates which accumulate at plasma membranes and disrupt cellular calcium homeostasis. The mechanism whereby Aβ disrupts calcium regulation
at the plasma membrane may involve the peptide forming calcium-conducting pores.

Calcium influx through glutamate receptors and voltage dependent channels mediates an array of functional and structural responses in neurons. However, unrestrained calcium influx can injure and kill neurons; such calcium overload can be induced by the excitatory transmitter glutamate and Alzheimer amyloid β-peptide, and is therefore implicated in both acute and chronic neurodegenerative conditions. Actin microfilaments are a major cytoskeletal element whose polymerization state is highly sensitive to calcium. Several key adaptive physiological processes in the brain, including neurotransmitter release, postsynaptic signalling and regulation of neurite outgrowth and synaptogenesis during development are triggered by calcium influx. However, excessive calcium influx plays a primary role in excitotoxicity, a form of neuronal injury resulting from overstimulation of glutamate receptors, and which is believed operative in a variety of both acute (e.g., stroke and traumatic brain injury) and chronic (e.g., Alzheimer’s and Huntington’s diseases) neurodegenerative conditions. In Alzheimer’s disease the 40–42 amino acid amyloid β-peptide which forms insoluble plaques in the brain may kill neurons by inducing Ca²⁺ influx and increasing sensitivity to excitotoxicity.

Actin and tubulin are two major structural proteins in neurons which polymerize to form microfilaments and microtubules, respectively. Microfilaments and microtubules are highly dynamic structures exquisitely sensitive to environmental stimuli that elevate [Ca²⁺], such as glutamate.

Stroke is our nation’s third leading killer and the number one cause of adult disability. One-half million people suffer a stroke each year. A stroke is the result of a sudden decrease in the flow of blood to an area of the brain. When blood cannot reach the brain, brain cells become deprived of oxygen and die. Consequently, functions normally controlled by the damaged brain area become impaired. For example, paralysis of certain body parts may occur. The interruption in blood flow can be due to blockage from a blood clot or narrowed artery in the head or neck or to the bursting of an artery in the brain.

Nerve cell injury and death is also responsible for other neurodegenerative disorders such as Down’s syndrome, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, Cerebral ischemia, cerebral infarction, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, pulmonary surgery, or cerebral trauma.

**SUMMARY OF THE INVENTION**

The present invention relates to a novel therapeutic use of certain compounds to protect nerve cells from injury and death. The compounds include cytochalasin D and related analogs, and cytochalasin E and related analogs. More particularly, the present invention concerns a method for reducing adverse effects of a neurodegenerative disorder comprising: administering to a patient a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by Formulas (I)–(II) and their pharmaceutically acceptable salts:

where R₁, R₂, R₂, R₃, R₄, R₅, R₆, and R₇ represent hydrogen, C₁ to C₆ alkyl or hydroxy, or where R₃ and R₄ together represent a carbonyl group; or

where R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀ represent hydrogen, C₁ to C₆ alkyl or hydroxy, or OAC, or where R₉ and R₁₀ together represent a carbonyl group.

The present invention also relates to a pharmaceutical composition comprising at least one compound selected from the group consisting of compounds represented by Formulas (I)–(II) and their pharmaceutically acceptable salts:

where R₁, R₂, R₃, R₄, R₅, R₆, and R₇ represent hydrogen, C₁ to C₆ alkyl or hydroxy, or where R₃ and R₄ together represent a carbonyl group; or

where R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀ represent hydrogen, C₁ to C₆ alkyl or hydroxy, or OAC, or where R₉ and R₁₀ together represent a carbonyl group.

Neurodegenerative disorders treatable by the present method include, but are not limited to, Alzheimer’s disease, Down’s syndrome, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, cerebral ischemia, cere-
bral infarction, thromboembolic and hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, pulmonary surgery, or cerebral trauma.

The present invention also relates to a method of attenuating intracellular calcium levels in mammalian nerve cells of a patient in need of therapy for amyloid-β peptide toxicity associated with neurodegenerative disorders which comprises administration to a mammal in need of such therapy an effective amount of a compound which attenuates intracellular calcium levels in the mammalian nerve cell.

Other features of the invention will become apparent in the course of the following description of the exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B, 1C and 1D show that cytochalasin D attenuates [Ca²⁺], responses to glutamate, Aβ and membrane depolarization.

FIGS. 2A-2D show cresyl violet-stained coronal sections from brains of rats administered kainate alone or kainate plus cytochalasin D.

FIG. 3 shows counts of viable neurons were made in region CA3 of Sham operated rats, and rats infused intraventricularly with vehicle or increasing concentrations of cytochalasin D prior to unilateral kainate injection into region CA1 of the hippocampus.

FIGS. 4A-4E show the effects of cytochalasin D and glutamate on actin filaments in cultured hippocampal cells.

FIGS. 5A and 5B show that cytochalasin D protects cultured hippocampal neurons against glutamate toxicity.

FIGS. 6A and 6B show that depolymerization of actin filaments is excitotoxic.

FIG. 7 shows that cytochalasin D does not protect hippocampal neurons against calcium ionophore toxicity.

FIG. 8 shows that cytochalasin D does not protect cultured hippocampal neurons against ion toxicity.

FIG. 9 shows that jasplakinolide, an actin filament-stabilizing agent, potentiates glutamate-induced elevation of [Ca²⁺] in cultured hippocampal neurons.

FIG. 10 shows that cytochalasin D does not affect [Ca²⁺] responses to calcium ionophore.

FIGS. 11A and 11B show the effects of cytochalasin D on actin filaments in cultured hippocampal cells.

FIGS. 12A and 12B show that cytochalasin D protects cultured hippocampal neurons against Aβ toxicity.

FIG. 13 shows that neurotoxicity induced by combined exposure to Aβ and glutamate is attenuated by cytochalasin D.

FIG. 14 Shows that cytochalasin E protection against Aβ toxicity is specific for actin-disrupting agents.

FIG. 15 shows that cytochalasin D does not protect neurons against hydrogen peroxide toxicity.

FIGS. 16A and 16B show that cytochalasin D attenuates Aβ-induced elevation of rest [Ca²⁺] and potentiation of [Ca²⁺] response to glutamate in cultured hippocampal neurons.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the inventors' surprising and unexpected discovery of a method for reducing adverse effects of a neurodegenerative disorder comprising: administering to a patient a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by Formulas (I)-(II) and their pharmaceutically acceptable salts:

where R₁, R₂, R₃, R₄, R₅, and R₆ represent hydrogen, C₃ to C₆ alkyl, hydroxy, or OAC, or where R₃ and R₄ together represent a carbonyl group, or

where R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, and R₁₇ represent hydrogen, C₁ to C₆ alkyl, hydroxy, or OAC, or where R₁₀ and R₁₁ together represent a carbonyl group.

The present invention is also based, in part, on the inventors' surprising and unexpected discovery of a method of attenuating intracellular calcium levels in mammalian nerve cells of a patient in need of therapy for amyloid-β peptide toxicity associated with neurodegenerative disorders which comprises administration to a mammal in need of such therapy an effective amount of a compound which attenuates intracellular calcium levels in the mammalian nerve cell.

Neurodegenerative disorders treatable by the present method include, but are not limited to, Alzheimer’s disease, Down’s syndrome, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, cerebral ischemia, cerebral infarction, thromboembolic and hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, pulmonary surgery, or cerebral trauma.

A preferred compound represented by Formula (I) is cytochalasin D and is sold commercially by Sigma Chemical Company under that name. Cytochalasin D has the following structural formula:
A preferred compound represented by Formula (II) is cytochalasin E and is sold commercially by Sigma Chemical Company under that name. Cytochalasin E has the following structural formula:

The compounds for use in the present invention can be administered as a pharmaceutical composition. The pharmaceutical compositions used in the methods of this invention for administration to humans and animals comprise an active agent in combination with a pharmaceutical carrier or excipient acceptable for delivery of the compounds to neurons.

The pharmaceutical compositions can be in the form of tablets (including lozenges and granules), dragees, capsules, pills, ampoules or suppositories comprising a compound of the invention. “Pharmaceutical composition” means physically discrete coherent portions suitable for medical administration. “Pharmaceutical composition in dosage unit form” means physically discrete coherent units suitable for medical administration, each containing a daily dose or a multiple (up to four times) or a sub-multiple (down to a fourth) of a daily dose of the active compound of the invention in association with a carrier and/or enclosed within an envelope. Whether the composition contains a daily dose, or for example, a half, a third or a quarter of a daily dose will depend on whether the pharmaceutical composition is to be administered once or, for example, twice, three times or four times a day, respectively.

Advantageously, the compositions are formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredients. Tablets, coated tablets, capsules, ampoules and suppositories are examples of preferred dosage forms according to the invention. It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be consistent with the dosage form employed in single or multiple unit doses. The exact individual dosages, as well as daily dosages, are determined according to standard medical principles under the direction of a physician or veterinarian.

The active agents can also be administered as suspensions, solutions or emulsions of the active compound in aqueous or non-aqueous diluents, syrups, granulates or powders. Diluents that can be used in pharmaceutical compositions (e.g., granulates) containing the active compound adapted to be formed into tablets, dragees, capsules and pills include the following: (a) fillers and extenders, e.g., starch, sugars, mannitol and silicic acid; (b) binding agents, e.g., carboxymethyl cellulose and other cellulose derivatives, alginites, gelatine and polyvinyl pyrrolidone; (c) moisturizing agents, e.g., glycerol; (d) disintegrating agents, e.g., agar-agar, calcium carbonate and sodium bicarbonate; (e) agents for retarding dissolution, e.g., paraffin; (f) resorption accelerators, e.g., quaternary ammonium compounds; (g) surface active agents, e.g., cetetyl alcohol, glycerol monostearate; (h) adsorptive carriers, e.g., kaolin and bentonite; (i) lubricants, e.g., talc, calcium and magnesium stearate and solid polyethylene glycols.

The tablets, dragees, capsules and pills comprising the active agent can have the customary coatings, envelopes and protective matrices, which may contain opacifiers. They can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes and protective matrices may be made, for example, from polymeric substances or waxes.

The active ingredient can also be made up in microencapsulated form together, with one or several of the above-mentioned diluents.

The diluents to be used in pharmaceutical compositions adapted to be formed into suppositories can, for example, be the usual water-soluble diluents, such as polyethylene glycols and fats (e.g., cocoa oil and high esters, e.g., C<sub>14</sub> + alcohols with C<sub>16</sub>-fatty acid) or mixtures of these diluents.

The pharmaceutical compositions which are solutions and emulsions can, for example, contain the customary diluents (with, of course, the above-mentioned exclusion of solvents having a molecular weight below 200, in the presence of a surface-active agent), such as diluents, dissolving agents and emulsifiers. Specific non-limiting examples of such diluents are water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzy alcohol, propanol, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (for example, ground nut oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitol or mixtures thereof.

For parenteral administration, solutions and suspensions should be sterile, e.g., water or arachis oil contained in ampoules and, if appropriate, blood-iso tonic.

The pharmaceutical compositions generally described above are suspensions can contain the usual diluents, such as liquid diluents, e.g., water, ethyl alcohol, propylene glycol, surface active agents (e.g., ethoxylated isostearol alcohols, polyoxyethylene sorbitol and sorbitan esters), poly crystalline cellulose, aluminium methahydroxide, agar-agar and tragacanth, or mixtures thereof.

The pharmaceutical compositions can also contain bulking agents and preservatives, as well as perfumes and flavoring additions (e.g., peppermint oil and eucalyptus oil, and sweetening agents, e.g., saccharin and aspartame).

The pharmaceutical compositions will generally contain from about 0.0001 to 90 wt. %, preferably about 0.01 to 10 wt. % of the active ingredient by weight of the total composition. In addition to the active agent, the pharmaceutical compositions and medicaments can also contain other pharmaceutically active compounds.

Any diluent in the pharmaceutical compositions of the present invention may be any of these mentioned above in relation to the pharmaceutical compositions. Such compositions may include solvents of molecular weight less than 200 as the sole diluent.

The active compound is administered perorally, parenterally (for example, intramuscularly, intraperitoneally,
neurons was assessed by morphological criteria. Neurons with intact neurites of uniform diameter and a soma with a smooth, round appearance were considered viable, whereas neurons with fragmented neurites and a vacuolated or swollen soma were considered nonviable. Survival values were expressed as percentages of the initial number of neurons present before experimental treatment. Statistical comparisons were made using ANOVA and Scheffe post-hoc tests for pairwise comparisons.

### Table 1

<table>
<thead>
<tr>
<th>Treatment Condition</th>
<th>Neuron Survival (% of control)</th>
<th>Cell Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle (DMSO)</td>
<td>100 ± 2.4</td>
<td></td>
</tr>
<tr>
<td>100 μM Cytochalasin D</td>
<td>97 ± 7.8</td>
<td></td>
</tr>
<tr>
<td>200 μM Cytochalasin D</td>
<td>91 ± 5.9</td>
<td></td>
</tr>
<tr>
<td>300 μM Cytochalasin D</td>
<td>87 ± 2.2</td>
<td></td>
</tr>
<tr>
<td>100 nM Colchicine</td>
<td>40 ± 5.2</td>
<td></td>
</tr>
<tr>
<td>85 ± 1.9</td>
<td>18 ± 5.4</td>
<td></td>
</tr>
<tr>
<td>150 μM Glutamate</td>
<td>43 ± 6.7</td>
<td></td>
</tr>
<tr>
<td>54 ± 7.4</td>
<td>42 ± 2.5</td>
<td></td>
</tr>
<tr>
<td>100 μM Glutamate + 10 nM CyD</td>
<td>12 ± 2.2</td>
<td></td>
</tr>
<tr>
<td>24 ± 7.4</td>
<td>47 ± 3.5</td>
<td></td>
</tr>
<tr>
<td>50 μM Aβ</td>
<td>55 ± 2.5</td>
<td></td>
</tr>
<tr>
<td>50 μM Aβ + 10 nM Cytochalasin D</td>
<td>74 ± 1.3</td>
<td></td>
</tr>
<tr>
<td>50 μM Aβ + 100 nM Cytochalasin D</td>
<td>23 ± 2.8</td>
<td></td>
</tr>
<tr>
<td>20 μM Glutamate</td>
<td>74 ± 0.7</td>
<td></td>
</tr>
<tr>
<td>50 μM Aβ + 20 μM Glutamate</td>
<td>24 ± 0.8</td>
<td></td>
</tr>
<tr>
<td>50 μM Aβ + 20 μM Glut = 63 ± 2.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values represent the means and SEM of 4 separate cultures (cell counts) or 4 culture wells (Alamar blue assay). *p<0.05 compared to control value. **p<0.001 compared to control value. ***p<0.001 compared to value for glutamate-treated cultures. *p<0.005 compared to value for glutamate-treated cultures. **p<0.001 compared to value for Aβ-treated cultures. ***p<0.001 compared to value for culture treated with 20 μM glutamate. *p<0.001 compared to cultures treated with 50 μM Aβ+20 μM glutamate. n.d. not determined.

At concentrations known to depolymerize actin, cytochalasin D alone (1–100 nM) had no significant effect on neuronal survival, while colchicine (100 nM) reduced survival (Table 1). Although cytochalasin D did not adversely affect neuronal survival, it did inhibit growth cone motility. Neuronal survival in cultures exposed to 100 μM glutamate for 24 hr was reduced to less than 20%. Glutamate neurotoxicity was significantly attenuated in cultures pretreated for 1 hr with cytochalasin D, whereas colchicine was ineffective (Table 1). Neuronal survival was reduced in less than 50% of control values in cultures exposed for 24 hr to 50 μM Aβ25–35 (Table 1). Aβ neurotoxicity was essentially eliminated in parallel culture cotreated with 100 nM cytochalasin D, whereas colchicine exacerbated Aβ toxicity (Table 1). Cytochalasin E(10–100 nM), another microfilament-disrupting agent, also protected cellular hippocampal neurons against the toxicities of glutamate and Aβ.

### Example 1

(hippocampal cell culture and experimental treatments)

Dissected embryonic rat hippocampal cell cultures were established and maintained. All procedures conformed with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the University of Kentucky Animal Care and Use Committee. Cultures were maintained on a polyethyleneimine-coated substrate in plastic 35-mm dishes or 96 well plates (for cell survival studies) or glass-bottom 35-mm dishes (for [Ca²⁺] imaging studies). The cell density was ~70–100 cells/mm². Cells were maintained in Eagle’s minimum essential medium supplemented 10% with fetal bovine serum and containing 20 mM sodium pyruvate. All experiments were performed in 6–10-day-old cultures, a time at which neurons exhibit calcium responses to glutamate mediated by both NMDA and α-aminoadon-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptors, and are vulnerable to excitotoxicity and Aβ toxicity. Aβ25–35 (Bachem, lot Z7444) and Aβ1–40 (Bachem, lot ZK600) were stored in the lyophilized form, and stocks were prepared immediately before use by dissolving the peptide at a concentration of 1 mM in sterile distilled water. Preliminary characterization of the aggregation kinetics and neurotoxicity profiles of each of these peptides showed that the peptides aggregated rapidly when placed in culture medium and progressively killed neurons over a 48-h period when added to cultures in a soluble form. Glutamate and colchicine (Sigma) were prepared as 200–500x stocks in saline. Cytochalasin D and E (Sigma) and calcium ionophore 4-bromo-A23187 (Calbiochem) were prepared as 500x stocks in dimethyl sulfoxide. Vitamin E (α-tocopherol; Sigma) was prepared as a 500x stock in ethanol. Borohydrguaraic acid and FeSO₄ were prepared as 50x stocks in sterile water.

### Example 2

(analyses of neuronal survival)

Neuronal survival was quantified by counting viable neurons in the same microscope fields (10x objective) immediately before experimental treatment and at time points after treatment. In addition, cells were grown in 96-well plates and Alamar blue fluorescence (Alamar Laboratories) was quantified by using a fluorescence plate reader. Alamar Blue is a non-fluorescent substrate that, after reduction by cell metabolites, becomes fluorescent. Usually neurons that died in the time intervals (20–48 h) between examination points were absent. Viability of the remaining
EXAMPLE 3

(measurement of [Ca]$^{2+}$)

Fluorescence ratio imaging of the Ca$^{2+}$ indicator dye fura-2 was used to quantify [Ca]$^{2+}$ in neuronal somata. Cells were incubated for 30–40 min in the presence of 2 μM acetoxymethyl ester form of the [Ca]$^{2+}$ indicator dye fura-2 and were then washed twice (2 ml/wash) with fresh medium and allowed to incubate at least 40 min before imaging. Immediately before imaging, the normal culture medium was replaced with Hanks’ balanced saline solution (GIBCO) containing 10 mM HEPES buffer and 10 mM of glucose. Cells were imaged using a Zeiss AxioFluor system with a 40x objective or Quantex system with a 40x oil objective. The ratio of the fluorescence emission using two different excitation wavelengths (334 and 380 nm) was used to determine [Ca]$^{2+}$. The system was calibrated using solutions containing either no Ca$^{2+}$ or a saturating level of Ca$^{2+}$ (1 mM) according to the following formula: [Ca]$^{2+}$ = Kf[R - R$_{min}$/ (R$_{max}$-R)] (F$_{max}$/F$_{min}$). Values represent the average [Ca]$^{2+}$ in the neuronal cell body. Experimental treatments were added to the bathing medium by dilution from 100–500x stocks.

EXAMPLE 4

(localization of phalloidin with fluorescence microscopy)

Hippocampal cells were exposed to cytochalasin D and then fixed for 30 min in 4% paraformaldehyde/phosphate-buffered saline. Cell membranes were permeabilized by incubating for 5 min in a solution of 0.2% Triton X-100 in phosphate-buffered saline. Cells were then incubated for 30 min in PBS containing 0.005 U/ml fluorescein-phalloidin (Molecular Probes). Cells were rinsed in water and mounted in Vectashield antifade solution (Vector Laboratories). Fluorescence images were acquired using a Sarastro 2000 confocal laser scanning microscope with a 60x oil-immersion objective. All images were acquired using identical settings for excitation intensity and detector gain.

EXAMPLE 5

Fura-2 calcium imaging technology revealed that cytochalasin D attenuated [Ca]$^{2+}$ responses to glutamate, Aβ, and membrane depolarization (FIG. 1). In control cultures, 50 μM glutamate induced a rapid approximately five-fold increase in neuronal [Ca]$^{2+}$. In contrast, the [Ca]$^{2+}$ response to glutamate in neurons pretreated with 100 nM cytochalasin D for 1 h was reduced by approximately 30% (FIG. 1A). The neuronal [Ca]$^{2+}$ response to glutamate was greatly enhanced in cultures pretreated with Aβ for 3 h; [Ca]$^{2+}$ rapidly rose to well over 1 μM compared to an increase to approximately 600 nM in neurons in untreated control cultures. Cytochalasin D completely blocked potentiation of [Ca]$^{2+}$ response to glutamate in Aβ-pretreated culture (FIG. 1B). Cytochalasin D pretreatment also suppressed K$^{+}$-induced elevation of [Ca]$^{2+}$ (FIG. 1C). Colchicine alone caused an elevation of rest [Ca]$^{2+}$, and did not attenuate [Ca]$^{2+}$ response to glutamate or Aβ (data not shown). Taken together with the previous patch clamp studies of Rosenmund and Westbrook and Johnson and Byerly, these data indicate that actin depolymerization reduces Ca$^{2+}$ influx induced by glutamate and membrane depolarization. Moreover, actin depolymerization abrogates the [Ca]$^{2+}$-destabilizing action of Aβ. The suppressive effect of cytochalasin D on glutamate-induced elevation of [Ca]$^{2+}$ was more pronounced with increasing concentrations of glutamate (FIG. 1D). Whereas the reduction in peak [Ca]$^{2+}$ response was only approximately 60 nM in neurons exposed to 10 μM glutamate, the reductions were approximately 170 and 460 nM in neurons exposed to 50 and 100 μM glutamate, respectively (FIG. 1D).

EXAMPLE 6

Kainate Lesion Paradigm

A kainate lesion paradigm was employed in adult rats to determine whether cytochalasin D was also excitoprotective. Twenty-four adult male Sprague-Dawley rats (250–300 g) were divided into the indicated experimental groups (4–5 rats/group). Kainate (0.5 mg/kg, i.p.) was injected stereotaxically into region CA1 of the right hippocampus of anesthetized rats. Cytochalasin D (the indicated concentration in 1 ml of saline-1% DMSO) or vehicle was infused into the right lateral ventricle during a 5–10 min period immediately following kainate injection. Rats were killed 48 h later and perfused transcardially with 4% paraformaldehyde. Brain sections (30 μm) were stained with cresyl violet and stained neurons in three adjacent 40X microscope fields of hippocampal region CA3 were counted (5 sections/rat). The neuronal counts were performed in sections removed approximately 200–400 μm from the injection site. This method results in highly reproducible, 75–99%, neuronal loss in the CA3 region in over 99% of the rats injected with kainate (calculations based on 302 rats receiving intrahippocampal kainate). Stereotaxic injection of a convulsant dose of kainate into region CA1 of the hippocampus resulted in selective damage to neurons in region CA3 evident 48 h following administration (FIG. 2). Infusion of cytochalasin D into the lateral ventricles immediately following injection of kainate resulted in a highly significant reduction in neuronal injury to CA3 neurons which was related to the dose of cytochalasin D (FIG. 2). Approximately 80% of the neurons were killed by kainate in control animals receiving an intracerebroventricular infusion of saline immediately following kainate administration.

The present data indicate that the cytoskeleton plays an active role in modulating potentially neurotoxic elevations of [Ca]$^{2+}$, and demonstrates that compounds that affect actin polymerization prove useful in alleviating neuronal injury and death in a variety of neurodegenerative conditions.

EXAMPLE 7

Intraventricular infusion of cytochalasin D immediately following injection of kainate resulted in a highly significant reduction in neuronal injury to CA3 neurons which was related to the dose of cytochalasin D (FIG. 3). Only 20% of the neurons were damaged by kainate in rats receiving 0.1 or 1.0 μg of cytochalasin D.

EXAMPLE 8

Cytochalasin D (10–1000 nM) caused a concentration-dependent reduction in phalloidin staining in neurons and loss of actin stress fibers in astrocytes, demonstrating its predicted disruptive effect on microfilaments (FIG. 4). Exposure of cultured neurons to increasing concentrations of glutamate also resulted in a concentration-dependent reduction in levels of phalloidin fluorescence (FIG. 4B). Glutamate did not reduce phalloidin staining in cultures incubated in Ca$^{2+}$-free medium indicating that Ca$^{2+}$ influx was required for the actin-depolymerizing action of glutamate (FIG. 4B).

EXAMPLE 9

Glutamate caused a dose-dependent reduction in neuronal survival during a 20-h exposure period with a maximum
killing of over 80% of the neurons with a glutamate concentration of 100 µM and an ED50 of approximately 35 µM (FIG. 5A). Exposure of cultures to cytochalasin D (1–1000 nM) prior to exposure to glutamate resulted in a highly significant dose-dependent increase in neuronal survival compared to parallel control cultures exposed to glutamate (FIG. 5A). The concentrations of cytochalasin D that were most effective in protecting neurons against glutamate toxicity were 10 and 100 nM, with higher concentrations not providing a further increase in neuronal survival. The protection against glutamate neurotoxicity afforded by cytochalasin D was most striking in cultures exposed to submaximally toxic concentrations of glutamate (e.g., 50 µM; FIG. 5B). Whereas 50 µM glutamate killed over 70% of the neurons in control cultures, fewer than 10% were killed in cultures pretreated with 100 nM cytochalasin D and then exposed to 50 µM glutamate (FIG. 5B). Cytochalasin D (10–100 nM) alone had no significant effect on neuronal survival during a 20-h exposure period (FIG. 5B).

EXAMPLE 10
Cytochalasin E also afforded significant protection against glutamate toxicity (FIG. 6A). The microtubule-disrupting agent colchicine did not protect neurons against glutamate toxicity (FIG. 6A), indicating that cytoskeletal disruption, in general, is not excitotoxic. If actin depolymerization was excitotoxic, then exposure of neurons to an agent that blocks microfilament depolymerization should increase vulnerability to glutamate toxicity. In order to test this prediction cultures were preincubated for 3 h in the presence of 10 µM jasplakinolide, a cyclic peptide which promotes actin polymerization, and then exposed to glutamate. Glutamate neurotoxicity was significantly potentiated in cultures treated with jasplakinolide (FIG. 6B), indicating that neurons are more vulnerable to excitotoxicity under conditions in which actin depolymerization does not occur.

EXAMPLE 11
Exposure of hippocampal cultures to increasing concentrations of A23187 resulted in a concentration-dependent reduction in neuronal survival (100–1000 nM) with essentially all neurons being killed by 1 µM A23187 (FIG. 7). The concentration-response curve for A23187 neurotoxicity in cultures pretreated with 100 nM cytochalasin D was essentially identical to that in control cultures, indicating that actin depolymerization was ineffective in protecting neurons against a Ca2+ mediated insult that does not involve Ca2+ influx through endogenous plasma membrane ion channels.

EXAMPLE 12
Exposure of hippocampal cultures to increasing concentrations of FeSO4 (10–100 nM) resulted in a concentration-dependent loss of neurons (FIG. 8). Neuronal loss induced by iron was not significantly altered in cultures pre-treated with 100 nM cytochalasin D, suggesting that the mechanism whereby cytochalasins protected against excitotoxicity did not involve an antioxidant effect. In contrast to cytochalasin D, two well-known antioxidants, vitamin E and nordihydroguaiaretic acid completely blocked the neurotoxicity of iron (FIG. 8).

EXAMPLE 13
In order to determine whether glutamate-induced disruption of actin filaments was involved in reducing [Ca2+], responses to glutamate, cultures were pretreated with the actin filament-stabilizing agent jasplakinolide and then exposed to glutamate. Glutamate-induced elevation of [Ca2+], was potentiated in neurons pretreated with jasplakinolide compared to control cultures (FIG. 9).

EXAMPLE 14
In contrast to its ability to suppress glutamate-induced elevation of [Ca2+], cytochalasin D did not attenuate the [Ca2+] response to 500 nm calcium ionophore A23187 (FIG. 10), suggesting that actin depolymerization specifically affects influx through plasma membrane channels as opposed to enhancement of Ca2+ extrusion or buffering. Colchicine (100 nM) did not attenuate [Ca2+] responses to glutamate.

EXAMPLE 15
Cells were exposed to 100 nM cytochalasin D for 1 h, membranes were permeabilized, and then cells were stained with fluorescein-labeled phalloidin. Cells were examined by confocal laser scanning microscopy and images of optical sections through neurons are shown in FIG. 11. In control cultures not exposed to cytochalasin D, intense phalloidin fluorescence was present in neurons where it appeared to be concentrated in the vicinity of the plasma membrane. In addition, growth cones stained intensely with phalloidin. Cytochalasin D caused a pronounced reduction in phalloidin staining in neurons, indicating loss of actin filaments (FIG. 11).

EXAMPLE 16
Exposure of cultured rat hippocampal neurons to increasing concentrations of Aβ25–35 resulted in a concentration-dependent reduction in neuronal survival during a 24-h incubation period (FIG. 12A). Aβ neurotoxicity was significantly attenuated in parallel cultures pretreated with 100 nM cytochalasin D. The amount of protection against Aβ neurotoxicity conferred by cytochalasin D was related to the concentration of cytochalasin D used. Significant protection occurred with 10 and 100 nM cytochalasin (FIG. 12B).

EXAMPLE 17
Exposure of neurons to both Aβ and glutamate resulted in significantly more neuronal death than in cultures exposed to either insult alone (FIG. 13). Cytochalasin D attenuated significantly neurotoxicity induced by combined exposure to Aβ and 20 µM glutamate (FIG. 13).

EXAMPLE 18
Cytochalasin E, another member of the cytochalasin family that selectively disrupts actin, attenuated Aβ neurotoxicity significantly (FIG. 14). In contrast, the microtubule-disrupting agent colchicine, at a concentration known to disrupt microtubules, did not protect neurons against Aβ toxicity (FIG. 14).

EXAMPLE 19
Exposure of hippocampal cultures to increasing concentrations of hydrogen peroxide resulted in a concentration-dependent reduction in neuronal survival during a 24-h exposure period (FIG. 15). Neuronal killing by hydrogen peroxide was not altered in cultures pretreated with 100 nM cytochalasin D, suggesting that this cytochalasin had little or no antioxidant activity. The neurotoxicity of hydrogen per-
oxide was largely prevented by pretreating cultures with the antioxidant vitamin E (FIG. 15), indicating that the toxicity of hydrogen peroxide was mediated largely by reactive oxygen species.

EXAMPLE 20

In control cultures, rest [Ca²⁺] was ~100 nM (FIG. 16A). Exposure of hippocampal cultures to 50 μM Aβ1 resulted in a significant increase in rest [Ca²⁺], rising to ~250 nM after 3 h of exposure and ~440 nM after 6 h (FIG. 16A). In parallel cultures pretreated with 100 nM cytochalasin D 1 h and then exposed to 50 μM Aβ1 for 3 and 6 h, the rest [Ca²⁺] was not significantly elevated (FIG. 16A). We therefore determined whether cytochalasin D would affect the enhancement of [Ca²⁺], responses to glutamate in neurons pretreated with Aβ1. As expected, the neuronal [Ca²⁺], response to glutamate (50 μM) was greatly enhanced in cultures pretreated with Aβ1 for 3 h; [Ca²⁺] rose rapidly to ~1,500 nM compared with an increase to ~500 nM in neurons in untreated control cultures (FIG. 16B). Cytochalasin D suppressed the Aβ1-induced enhancement of the [Ca²⁺] response to glutamate. In contrast to its ability to suppress [Ca²⁺], responses to Aβ1 and glutamate, cytochalasin D did not attenuate the [Ca²⁺] response to 500 nM calcium ionophore A23187 (data not shown), suggesting that the major action of cytochalasin D was a reduction in calcium influx rather than an enhancement of calcium extrusion or buffering.

DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1. Cytochalasin D attenuates [Ca²⁺], represents a glutamate, Aβ1, and membrane depolarization in cultured hippocampal neurons.

(A) Cultures were pretreated for 1 hr with 100 nM cytochalasin D and then [Ca²⁺], in neurons was monitored prior to and following exposure to 50 μM glutamate. The records represent the mean [Ca²⁺], in 8–12 neurons. Similar results were obtained in 4 separate experiments.

(B) Aβ1-induced potentiation of [Ca²⁺], response to glutamate is abrogated by cytochalasin D. Cultures were left untreated (Control) or were exposed to 20 μM Aβ25–35 for 6 hr or cytochalasin D plus Aβ25–35 for 6 hr. The [Ca²⁺] was then monitored prior to following exposure to 50 μM glutamate. Values represent the means of 8–14 neurons. Similar results were obtained in 3 separate experiments.

(C) Cultures were pretreated for 3 hr with 50 μM Aβ1 alone or in combination with 100 nM cytochalasin D. The [Ca²⁺], in neurons was then monitored prior to and following exposure to 50 μM KCl. Values represent the mean of 14–23 neurons. Similar results were obtained in a separate experiment.

(D) Cultures were pretreated for 1 hr with 100 nM cytochalasin D. The [Ca²⁺], in neurons was measured immediately prior to, and at 5 min following, exposure to the indicated concentrations of glutamate. Values represent the means and SEM of determinations made in 17–26 neurons. *P<0.05 (10 μM glutamate), P<0.02 (50 μM glutamate), P<0.01 (100 μM glutamate) compared to corresponding control values.

FIG. 2. Cytochalasin D protects hippocampal neurons against kainate toxicity in vivo.

Cresyl violet-stained coronal sections from brains of rats administered kainate alone (left) or kainate plus cytochalasin D (CyD; right). Note damage to CA3 neurons induced by kainate, and marked reduction in the damage in the rat receiving cytochalasin D (arrows). Lower micrographs are high magnification of a region of CA3 from the sections shown in the upper panels.

FIG. 3. Counts of viable neurons were made in region CA3 of Sham-operated rats, and rats infused intraventricularly with vehicle or increasing concentration of cytochalasin D prior to unilateral kainate injection into region CA1 of the hippocampus. Neuronal survival in the kainate injected hippocampus is expressed as a percentage of neurons in the contralateral hippocampus. Values represent the mean and SEM (4 or 5 rats/group). *P<0.01 compared to value for sham rats. **P<0.01 compared to value for vehicle-infused rats. (ANOVA with Scheffe’s post-hoc test).

FIG. 4. (A) Micrographs are confocal laser scanning microscope images of cultured hippocampal cells stained with fluorescein-labeled phalloidin. Cells were exposed for 3 h to either vehicle (control; left) or 100 nM cytochalasin D (right) prior to staining with phalloidin. The top micrographs show several neurons (arrowheads point to neuronal cell bodies); note reduction in phalloidin fluorescence in cytochalasin-treated neurons. The bottom micrographs show astrocytes; note intense staining of stress fibers in control astrocytes (e.g., arrowhead) and loss of stress fibers and cell rounding in cytochalasin-treated astrocytes.

(B) Cytochalasin D and glutamate cause a reduction in neuronal phalloidin fluorescence. Parallel cultures were exposed to vehicle (control), cytochalasin D (10, 100, and 1000 nM), or glutamate (50, 100, and 200 μM) for 3 h. Additional cultures were incubated in Ca²⁺-free medium (no added Ca²⁺ plus 1 mM EGTA) and exposed to cytochalasin D or glutamate for 3 h. Cells were then fixed and stained with fluorescein-labeled phalloidin. Values represent the mean fluorescence intensity per neuronal cell body (±SEM; n=15–18). The reduction in phalloidin fluorescence in neurons exposed to increasing concentrations of cytochalasin D and glutamate were highly significant (P<0.0001 by ANOVA).

FIG. 5. Cultures were exposed to the indicated treatments for 20 h. Cytochalasin D was added to cultures 30 min prior to exposure to glutamate, and control cultures were exposed to 0.2% dimethylsulfoxide.

(A) Neuronal survival was quantified in cultures that had been pretreated with the indicated concentrations of cytochalasin D and then exposed to 50 μM glutamate for 20 h. Values represent the means and SEM of determinations made in four separate cultures. The overall effect of cytochalasin D in increasing neuronal survival was highly significant (P<0.0001 by ANOVA). Pairwise statistical comparisons of cytochalasin-treated cultures with the control survival (Scheffee’s test) indicated 1 nM cytochalasin D, P<0.05; 10 nM cytochalasin D, P<0.0001; 100 and 1000 nM cytochalasin D, P<0.0001.

(B) Neuronal survival was quantified in cultures that had been pretreated with either vehicle (control) or 100 nM cytochalasin D and then exposed to the indicated concentrations of glutamate for 20 h. Values represent the means and SEM of determinations made in four separate cultures. Neuronal survival was significantly greater in cultures pretreated with cytochalasin D and exposed to 10 μM glutamate (P<0.05), 50 μM glutamate (P<0.001), and 100 μM glutamate (P<0.02). ANOVA with Scheffe’s post hoc test.

FIG. 6. (A) Cultures were pretreated with 100 nM cytochalasin D (CyD), 100 nM cytochalasin E (CyE), or 100 nM colchicine (Colc). Cultures were then exposed to 50 μM glutamate for 20 h. Values for neuronal survival represent the means and SEM of determinations made in four separate cultures. *P<0.01 compared to control value. **P<0.001 compared to value for cultures exposed to glutamate alone.

(B) Cultures were pretreated for 1 h with 5 μM jasplakonic acid or vehicle and then exposed for 20 h to the indicated
concentrations of glutamate. Values represent the means and SEM of determinations made in four separate cultures. *P<0.01 compared to value for cultures exposed to 20 μM glutamate alone. **P<0.05 compared to cultures exposed to 50 μM glutamate alone.

FIG. 7. Cultures were pretreated for 1 h with 0.2% dimethylsulfoxide (control) or 100 nM cytochalasin D. Calcium ionophore A23187 was then added at the indicated concentrations and neuronal survival was assessed 8 h later. Values represent the means and SEM of determinations made in four separate cultures.

FIG. 8. Cultures were preincubated 1 h in the presence of 0.5% dimethylsulfoxide (control), 100 nM cytochalasin D, 50 μg/ml vitamin E (ViE), or 2 μM nordihydroguaiaretic acid (NDGA). Cultures were then exposed for 6 h to the indicated concentrations of FeSO₄, and neuronal survival was quantified. Values represent the means and SEM of determinations made in four separate cultures. *P<0.01 compared to value for cultures exposed to 100 μM FeSO₄ alone.

FIG. 9. Cultures were pretreated for 3 h with vehicle (control) or 10 μM jasplakinolide. The [Ca²⁺] was monitored prior to and following exposure to 50 μM glutamate. Values represent the mean of determinations made in 10–12 neurons. Similar results were obtained in two additional experiments.

FIG. 10. Cytochalasin D does not affect [Ca²⁺] responses to calcium ionophore. Cultures were pretreated with 100 nM cytochalasin D or vehicle (control). The [Ca²⁺] was monitored prior to and following exposure to 500 nM calcium ionophore A23187. Values represent the mean of 12–20 neurons. Similar results were obtained in a separate experiment.

FIG. 11. Micrographs are confocal laser scanning microscope images of cultured hippocampal cells stained with fluorescein-labeled phalloidin. Cells were exposed for 1 h to either vehicle (Control) or 100 nM cytochalasin D before fixation and staining with FITC-phalloidin. Each panel shows several neurons. Note intense fluorescence in peripheral regions of cell bodies (e.g., arrowheads) and in growth cones (arrow) in control cultures and loss of fluorescence in cytochalasin-treated neurons (arrowheads point to edge of neuronal cell bodies).

FIG. 12. (A) Cultures were pretreated for 1 h with vehicle 0.2% dimethyl sulfoxide (Control) or 100 nM cytochalasin D (CydD) and were exposed to the indicated concentrations of Aβ25–35 for 48 h. Data are mean and SEM values of determinations made in four separate cultures. Neuronal survival was significantly increased in cytochalasin D-treated cultures exposed to 20 μM Aβ (p<0.05) and 50 μM Aβ (p<0.01).

(B) Cultures were pretreated for 1 h with the indicated concentrations of cytochalasin D and then exposed to 50 μM Aβ25–35; parallel cultures were exposed to cytochalasin D alone (Control). Data are mean and SEM values of determinations made in four separate cultures. Neuronal survival was significantly increased in Aβ-treated cultures exposed to 10 or 100 nM cytochalasin D (p<0.01).

FIG. 13. Cultures were exposed to 50 μM Aβ alone; 20 μM glutamate alone; 50 μM Aβ plus 20 μM glutamate; or 100 nM cytochalasin D plus 50 μM Aβ plus 20 μM glutamate. Neuronal survival was assessed 48 h after treatment. Data are mean and SEM values of determinations made in four separate cultures. *P<0.05 compared to value for cultures exposed to Aβ alone; and p<0.01, compared with cultures exposed to glutamate alone. **P<0.01, compared with value for cultures exposed to Aβ plus glutamate.

FIG. 14. Cultures were exposed to 100 nM colchicine; 50 μM Aβ; 100 nM colchicine plus 50 μM Aβ; 100 nM cytochalasin E (CyD) plus Aβ (colchicine and cytochalasin E were added 1 h before Aβ); neuronal survival was assessed 48 h later. Data are mean and SEM values of determinations made in four separate cultures. *p<0.01, compared with values for control or colchicine alone. **p<0.01, compared with value for cultures exposed to Aβ alone.

FIG. 15. Cytochalasin D does not protect neurons against hydrogen peroxide toxicity. Cultures were pretreated for 1 h with vehicle (Control), 100 nM cytochalasin D (CydD), or 50 μg/ml vitamin E (ve) and then exposed for 20 h to the indicated concentrations of hydrogen peroxide. Data are mean and SEM values of determinations made in four separate cultures.

FIG. 16. Cytochalasin D attenuates Aβ-induced elevation of rest [Ca²⁺], and potentiation of [Ca²⁺], response to glutamate in cultured hippocampal neurons.

(A) Cultures were exposed to the indicated treatments and [Ca²⁺] was determined in neurons at 3 and 6 h after treatment. CyD, cytochalasin D (100 nM; added 1 h before exposure to Aβ); Abeta (50 μM Aβ25–35). Data are mean and SEM values of determinations made in 17–24 neurons in three separate cultures per time point.

(B) Aβ-induced potentiation of [Ca²⁺] response to glutamate is abrogated by cytochalasin D. Cultures were left untreated (Control) or were exposed to 20 μM Aβ25–35 for 6 h or cytochalasin D plus Aβ25–35 for 6 h. The [Ca²⁺] was then monitored before and after exposure to 50 μM glutamate (glutamate was added at the time point indicated by the arrow). Data are mean values of eight to 14 neurons. Similar results were obtained in three separate experiments.

The purpose of the above description and examples is to illustrate some of the results of the present invention without implying any limitation. It will be apparent to those of skill in the art that various modifications and variations may be made to the composition and method of the present invention without departing from the spirit or scope of the invention. All patents and publications cited in the bibliography citation below are incorporated by reference in their entirety.

REFERENCES


75. Mattson, M. P. et al., Calcium destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res. 621:35–49; 1993.


What is claimed is:

1. A method for reducing adverse effects of a neurodegenerative disorder comprising: administering to a subject a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by Formulas (I)-(II) and their pharmaceutically acceptable salts:

![Formula (I)](image)

where R1, R2, R3, R4, R5, R6, and R7 represent hydrogen, C1 to C6 alkyl or hydroxy, or where R3 and R4 together represent a carbonyl group; or

![Formula (II)](image)

where R1, R2, R3, R4, R5, R6, R7, and R8 represent hydrogen, C1 to C6 alkyl or hydroxy, or OAC, or where R5 and R6 together represent a carbonyl group.

2. A method according to claim 1, wherein the compound is represented by formula (I) or pharmaceutically acceptable salts thereof.

3. A method according to claim 2, wherein the compound is cytochalasin D.
4. A method according to claim 1, wherein the compound is represented by formula (II) or pharmaceutically acceptable salts thereof.

5. A method according to claim 4, wherein the compound is cytochalasin E.

6. A method according to claim 1, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer’s disease, Down’s syndrome, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, cerebral ischemia, cerebral infarction, thromboembolic and hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, pulmonary surgery, and cerebral trauma.

* * * * *